Published in Rheumatol Int on June 28, 2009
Pathogenesis of ankylosing spondylitis. Nat Rev Rheumatol (2010) 1.23
Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. Br J Clin Pharmacol (2012) 1.10
The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review. Arthritis Res Ther (2010) 0.98
Epigenetics and the transition from acute to chronic pain. Pain Med (2012) 0.93
Thalidomide reduces recurrence of ankylosing spondylitis in patients following discontinuation of etanercept. Rheumatol Int (2012) 0.83
Increased occurrence of spinal fractures related to ankylosing spondylitis: a prospective 22-year cohort study in 17,764 patients from a national registry in Sweden. Patient Saf Surg (2013) 0.82
Anti-tumor necrosis factor drug survival in axial spondyloarthritis is independent of the classification criteria. Rheumatol Int (2014) 0.76
The synergistic efficacy of adalimumab and pamidronate in a patient with ankylosing spondylitis. Clin Rheumatol (2010) 0.75
Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum (1984) 20.51
Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med (2002) 6.26
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (2002) 6.12
Clinical guidelines: developing guidelines. BMJ (1999) 6.01
Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum (2000) 4.62
Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum (2005) 4.12
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2006) 3.51
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum (2003) 3.47
Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum (2005) 3.31
Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int (2002) 2.95
Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum (2003) 2.91
How to diagnose axial spondyloarthritis early. Ann Rheum Dis (2004) 2.91
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum (2003) 2.78
The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum (2005) 2.74
Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol (2002) 2.71
Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum (2008) 2.71
Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum (2001) 2.49
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis (2004) 2.26
Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum (2003) 2.20
Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum (1995) 2.16
The outcome of ankylosing spondylitis: a study of 100 patients. Br J Rheumatol (1997) 2.13
The natural disease course of ankylosing spondylitis. Arthritis Rheum (1983) 2.10
Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res (1999) 2.00
A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum (2002) 1.97
No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis (2006) 1.94
Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis (2006) 1.86
Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) (2005) 1.82
Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis (2000) 1.79
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis (2004) 1.76
Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis (2002) 1.76
Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum (2001) 1.68
BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Rheumatology (Oxford) (2005) 1.66
Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum (1999) 1.65
Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol (2007) 1.63
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther (2005) 1.61
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis (2004) 1.53
Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) infliximab in ankylosing spondylitis: 4-year followup. J Rheumatol (2006) 1.49
Conventional treatments for ankylosing spondylitis. Ann Rheum Dis (2002) 1.48
Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum (2005) 1.46
Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum (2002) 1.41
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum (2005) 1.41
MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis (2007) 1.40
Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford) (2004) 1.37
Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis (2005) 1.37
Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis (2005) 1.35
Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum (1996) 1.35
Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev (2006) 1.34
The course of established ankylosing spondylitis and the effects of sulphasalazine over 3 years. Br J Rheumatol (1993) 1.31
Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis (2003) 1.31
Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. J Rheumatol (1996) 1.30
Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis (2005) 1.29
Anatomic structures involved in early- and late-stage sacroiliitis in spondylarthritis: a detailed analysis by contrast-enhanced magnetic resonance imaging. Arthritis Rheum (2003) 1.29
Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford) (1999) 1.28
The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis. Rheumatology (Oxford) (2005) 1.27
Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. Br J Rheumatol (1996) 1.27
Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol (2001) 1.26
Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum (2005) 1.25
Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol (2000) 1.23
MRI of the sacroiliac joints in patients with moderate to severe ankylosing spondylitis. AJR Am J Roentgenol (2006) 1.22
Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann Rheum Dis (2005) 1.21
Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis (2007) 1.20
Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford) (2007) 1.18
Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum (1988) 1.18
The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology (Oxford) (2004) 1.17
Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis (2007) 1.17
Sulphasalazine in ankylosing spondylitis. Ann Rheum Dis (1986) 1.16
Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology (Oxford) (2005) 1.15
Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis (2007) 1.15
Six months open label trial of leflunomide in active ankylosing spondylitis. Ann Rheum Dis (2005) 1.14
Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis (2004) 1.14
Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology (Oxford) (2007) 1.11
Is methotrexate effective in ankylosing spondylitis? Rheumatology (Oxford) (2002) 1.10
Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol (2001) 1.09
Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum (2006) 1.07
Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol (2004) 1.06
Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol (2001) 1.05
Fatigue in patients with ankylosing spondylitis: A comparison with the general population and associations with clinical and self-reported measures. Arthritis Rheum (2005) 1.04
Sulphasalazine therapy in ankylosing spondylitis: its effect on disease activity, immunoglobulin A and the complex immunoglobulin A-alpha-1-antitrypsin. Br J Rheumatol (1989) 1.04
Marginal erosive discovertebral "Romanus" lesions in ankylosing spondylitis demonstrated by contrast enhanced Gd-DTPA magnetic resonance imaging. Skeletal Radiol (2000) 1.02
Meta-analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol (1990) 0.97
Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol (2000) 0.97
An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol (1998) 0.97
Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. Joint Bone Spine (2007) 0.93
Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis (2004) 0.92
Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis (2005) 0.91
Disease activity in longstanding ankylosing spondylitis: a correlation of clinical and magnetic resonance imaging findings. Clin Rheumatol (2007) 0.90
Discovertebral destruction in ankylosing spondylitis: the role of computed tomography and magnetic resonance imaging. Br J Radiol (1990) 0.90
Corticosteroid injection of the sacroiliac joint in patients with seronegative spondylarthropathy. Arthritis Rheum (1992) 0.90
Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum Dis (2007) 0.89
Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol (2006) 0.89
Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment. Clin Rheumatol (1991) 0.89
Imaging in ankylosing spondylitis. Best Pract Res Clin Rheumatol (2006) 0.88
Treatment of active ankylosing spondylitis with pamidronate. Rheumatology (Oxford) (2003) 0.87
Magnetic resonance imaging guided corticosteroid injection of the sacroiliac joints in patients with therapy resistant spondyloarthropathy: a pilot study. J Rheumatol (2000) 0.83
Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up. Rheumatology (Oxford) (2006) 0.82
Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis (2005) 0.82
Efficacy of sacroiliac corticosteroid injections in patients with inflammatory spondyloarthropathy: results of a 6 month controlled study. J Rheumatol (2000) 0.81
Infliximab in severe active ankylosing spondylitis with spinal ankylosis. Intern Med J (2008) 0.80
Treatment of ankylosing spondylitis with pamidronate: an open label study. Ann Rheum Dis (2006) 0.77
Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology (2001) 2.13
Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nat Med (1995) 1.81
Rheumatology curriculum: passport to the future successful handling of the musculoskeletal burden? Rheumatology (Oxford) (2004) 1.52
The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene (1994) 1.51
Pregnancy in a rheumatoid arthritis patient on infliximab and methotrexate. Rheumatology (Oxford) (2004) 1.42
Synovial fluid and plasma kinetics of repeat dose sustained action tiaprofenic acid in patients with rheumatoid arthritis. Drugs (1988) 1.39
Prevalence of insulin-dependent diabetes mellitus in Asian children. Diabet Med (1987) 1.30
Diabetic renal disease: differences between Asian and white patients. Br Med J (Clin Res Ed) (1986) 1.29
Referrals from general practice to a rheumatology clinic. Br J Rheumatol (1988) 1.25
Questionnaire survey of diabetic care in general practice in Leicestershire. Health Trends (1985) 1.20
Campylobacter pylori colonization factor shows specificity for lactosylceramide sulfate and GM3 ganglioside. Biochem Int (1989) 1.08
Adverse reactions during treatment with amiodarone hydrochloride. Br Med J (Clin Res Ed) (1983) 1.07
Biophysical properties and molecular characterization of amiloride-sensitive sodium channels in A549 cells. Am J Physiol Lung Cell Mol Physiol (2000) 1.04
Modification of biophysical properties of lung epithelial Na(+) channels by dexamethasone. Am J Physiol Cell Physiol (2000) 0.97
The effect of short term intensive insulin therapy in non-insulin-dependent diabetics who had failed on sulphonylurea therapy. Diabetes Res (1986) 0.95
Haemangioma of the maxilla. J Laryngol Otol (1988) 0.93
TEL-AML1 preleukemic activity requires the DNA binding domain of AML1 and the dimerization and corepressor binding domains of TEL. Oncogene (2007) 0.93
Comparative study of bone mineral density, calcium, and vitamin D status in the Gujarati and white populations of Leicester. Postgrad Med J (2003) 0.92
Diabetes mellitus as a risk factor for acute myocardial infarction in Asians and Europeans. Br Heart J (1989) 0.90
Diabetes in Asian children. Lancet (1990) 0.88
Aplastic anaemia in systemic lupus erythematosus: a cellular immune mechanism? Br J Rheumatol (1991) 0.88
Aberrant processing of oxidative DNA damage in systemic lupus erythematosus. Biochem Biophys Res Commun (2000) 0.85
Eating habits in Asian diabetics. Diabet Med (1986) 0.84
Fever, myalgia, and arthralgia in a patient on captopril and allopurinol. Lancet (1984) 0.83
Physical fitness training for wheelchair ambulation by the arm crank propulsion technique. Clin Rehabil (2001) 0.81
Isolation and characterization of a neu protein-specific activating factor from human ATL-2 cell conditioned medium. Biochem Biophys Res Commun (1991) 0.81
The effects of high dose inhaled beclomethasone dipropionate on glucose and lipid profiles in normal and diet controlled diabetic subjects. Respir Med (1989) 0.81
An unusual presentation of Baker's cyst in a patient with rheumatoid arthritis. Br J Rheumatol (1988) 0.81
A fresh look at polymyalgia rheumatica. Rheumatology (Oxford) (2002) 0.81
Plasma glucose responses to glucose, sucrose, and honey in patients with diabetes mellitus: an analysis of glycaemic and peak incremental indices. Diabet Med (1985) 0.81
Aerobic capacity of the brick-field workers in eastern India. Ind Health (1994) 0.80
Treatment of vasculitis. Br J Clin Pharmacol (1993) 0.80
Energy cost and locomotor performance of the low-cost arm-lever-propelled three-wheeled chair. Int J Rehabil Res (2001) 0.80
Improved effect of tolbutamide when given before food in patients on long-term therapy. Br J Clin Pharmacol (1984) 0.79
Gastric hemorrhage and Kaposi's sarcoma treated with radiotherapy. N J Med (1991) 0.78
Energy expenditure in manual load carriage. Ind Health (1981) 0.78
Spectroscopic and theoretical investigations on effective and selective interaction of fullerenes C60 and C70 with a derivatized Zn-phthalocyanine: stabilization of charge-recombined state by side-on approach of C70. J Phys Chem A (2010) 0.77
Primary pulmonary hypertension associated with systemic lupus erythematosus. Clin Rheumatol (1991) 0.77
Physiological response to the ambulatory performance of hand-rim and arm-crank propulsion systems. J Rehabil Res Dev (2001) 0.76
Evaluation of anti-infective potential of a tribal folklore Odina wodier Roxb against some selected microbes and herpes simplex virus associated with skin infection. J Appl Microbiol (2013) 0.76
Estimation of maximum permissible loads to be carried by Indians of different ages. Ergonomics (1987) 0.75
Photochemical E (trans)-->Z (cis) isomerization in substituted 1-naphthylacrylates. J Org Chem (2001) 0.75
First myocardial infarction in Asian and white men. BMJ (1989) 0.75
Gold therapy in rheumatoid arthritis. Lancet (1991) 0.75
Diabetes in an urban population in south India. BMJ (1988) 0.75
Thoracic inlet compression due to amiodarone induced goitre. Postgrad Med J (1985) 0.75
Metastatic follicular carcinoma of the thyroid presenting with thyrotoxic induced impaired control of diabetes mellitus. Postgrad Med J (1986) 0.75
Identification of a 140 kDa protein of rat presynaptic terminal membranes encompassing the active zones. Brain Res (1995) 0.75
Bilateral radicular cysts. Oral Surg Oral Med Oral Pathol (1976) 0.75
Glucose tolerance following strokes in the elderly. Age Ageing (1986) 0.75
An evidence-based approach to the management of low back pain and sciatica: how the evidence is applied in clinical cases. Musculoskeletal Care (2003) 0.75
Evaluation of ambulatory performance of the arm propelled three-wheeled chair using heart rate as a control index. Disabil Rehabil (2000) 0.75
Periapical actinomycosis. Oral Surg Oral Med Oral Pathol (1975) 0.75
A physiological study of manual lifting of loads in Indians. Ergonomics (1981) 0.75
Phase-transfer catalyst-induced changes in the absorption and fluorescence behavior of some electron donor-acceptor molecules. J Am Chem Soc (2001) 0.75
Polymyalgia rheumatica with bilateral subclavian artery occlusion. Br J Rheumatol (1987) 0.75
Aspects of the socio-economic impact of malarial fever in colonial Bengal. Bengal Past Present (1999) 0.75
Insulin and C-peptide in ascitic fluid and plasma and their relative responses to glucagon in patients with cirrhosis. J Endocrinol Invest (1988) 0.75
Dietary habits of Asian diabetics in a general practice clinic. Hum Nutr Appl Nutr (1987) 0.75
Management of the acutely ill diabetic patient. Intensive Care Nurs (1986) 0.75
Penicillamine in rheumatoid arthritis. A problem of toxicity. Drug Saf (1992) 0.75
Iron deficiency anaemia in chronic inflammatory rheumatic diseases: low mean cell haemoglobin is a better marker than low mean cell volume. Ann Rheum Dis (2005) 0.75
Development of amphotericin B loaded nanoparticles. Boll Chim Farm (1998) 0.75
Infected foreign body due to Bacillus licheniformis in rheumatoid arthritis. Br J Rheumatol (1990) 0.75
A comparative study of sulphonylurea and insulin therapy in non insulin dependent diabetics who had failed on diet therapy alone. Diabetes Res (1987) 0.75
Energy cost of manual wheelchair propulsion at different speeds. Int J Rehabil Res (2002) 0.75
Insulin secretion to glucose infusion in gestational diabetes subjects with differing DNA polymorphisms flanking the insulin gene. Diabetes Res (1987) 0.75
Tuning the size and optical properties in molecular nano/microcrystals: manifestation of hierarchical interactions. Small (2006) 0.75
Aphthous ulcers. Br Dent J (2002) 0.75
Overseas medical graduates in the United Kingdom. N Engl J Med (1987) 0.75
Variability and reproducibility of glycaemic and peak incremental indices and their value in predicting the glycaemic response to food. Diabete Metab (1988) 0.75
Arm-crank propelled three-wheeled chair: physiological evaluation of the propulsion using one arm and both arm patterns. Int J Rehabil Res (2004) 0.75